Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

  • Challenge: Predicting progression

Oxford researchers are analysing and linking comprehensive primary to secondary care electronic health records (EHRs) and molecular stratification outputs from prospective studies such as the OxPLoreD programme. This will allow clinicians to better predict which individuals with MGUS will progress to myeloma and intercept and treat those most likely to progress, for example in the DEFENCE trial.